President Donald Trump revealed on Tuesday that Pfizer has agreed to lower the prices of prescription drugs offered through Medicaid. At the same time, he announced plans to launch a new platform called “TrumpRx,” designed to let Americans purchase prescription medications at discounted rates directly, bypassing insurance.
Trump emphasized that the initiative aims to improve healthcare access, particularly for low-income Americans. “This is a critical step forward in our work to help hard-working, low-income Americans,” he said, noting the significant relief it could provide for those struggling with medication costs.
A senior administration official indicated that the TrumpRx website could be operational by early 2026. The platform is intended to be a central hub where Americans can compare prices and access medications at the lowest available rates, providing a direct-to-consumer option that does not rely on insurance coverage.
Current direct-to-consumer pricing is often below full cash prices but can still exceed insured out-of-pocket costs. For example, the weight loss drug Wegovy costs over $1,000 monthly at full cash price, $499 via direct-to-consumer platforms, and as little as $25 for those with insurance coverage.
